INLIF Limited filed a 6-K attaching notice and proxy materials for an extraordinary general meeting scheduled for August 17, 2026. Shareholders are voting on proposals to increase authorized share capital from US$350,000 to US$2.72 billion by creating approximately 8.5 billion new Class A and B ordinary shares. The filing also proposes reducing the par value of all ordinary shares from US$0.32 to US$0.0001 through a capital reduction and subdivision process. Additionally, shareholders will vote on adopting amended articles of association to reflect these changes and ratify Enrome LLP as the independent auditor for fiscal year 2026. INLIF Limited operates in the medical device industry, specifically focusing on minimally invasive surgical instruments.

On July 20, 2026, INLIF Limited entered into a securities purchase agreement with Kerui Enterprise Limited for the issuance and sale of 40,000 Class B ordinary shares at $2.58 per share, totaling $103,200 in gross proceeds. The transaction closed on July 22, 2026, and the company intends to use the proceeds for general corporate purposes and working capital. INLIF Limited is a Cayman Islands exempted company that operates in the general corporate sector.

On June 30, 2026, INLIF Limited announced a 1-for-200 share combination of all authorized and issued ordinary shares to enhance financial flexibility and support Nasdaq compliance. The combination became effective for trading on July 6, 2026. Following the action, the company's authorized share capital consists of 1,046,875 Class A and 46,875 Class B ordinary shares with a par value of $0.32 each. The company updated its Memorandum and Articles of Association to reflect these changes. INLIF Limited operates in the healthcare industry, providing medical services and products.